Estimation of fracture risk by the FRAX tool in patients with systemic lupus erythematosus: a 10-year longitudinal validation study

被引:2
作者
Mok, Chi Chiu [1 ]
Tse, Sau Mei [2 ]
Chan, Kar Li [2 ]
Ho, Ling Yin [2 ]
机构
[1] Tuen Mun Hosp, Dept Med, Tuen Mun, Tsing Chung Koon Rd, Hong Kong, Peoples R China
[2] Tuen Mun Hosp, Dept Med, Hong Kong, Peoples R China
关键词
fracture; glucocorticoid; lupus; osteoporosis; risk; RHEUMATOLOGY; GUIDELINES;
D O I
10.1177/1759720X221074451
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The fracture risk assessment tool has been widely used to stratify the 10-year fracture risk to guide therapy. Using the actual fracture data of a 10-year longitudinal cohort of older patients with systemic lupus erythematosus, we reported an underestimation of the tool in predicting major symptomatic osteoporotic fractures. Treatment of osteoporosis in systemic lupus erythematosus should not be based on fracture risk estimation alone. Relevant time-dependent risk factors should be taken into account for an individualized decision. Objective: To compare the observed fracture incidence in a 10-year longitudinal cohort of patients with systemic lupus erythematosus (SLE) with the fracture risk prediction from the fracture risk assessment (FRAX) tool. Methods: Adult patients (> 40 years) with SLE who had a first DEXA scan performed in 2005-2009 were studied. The 10-year rates of major osteoporotic and hip fractures were estimated by FRAX using clinical data at DEXA with adjustment for prednisolone dosage. The actual incidence of clinical fractures at 10 years was compared with the estimated rates. Factors associated with new fractures were studied by logistic regression. Results: A total of 229 SLE patients were studied (age: 50.2 +/- 6.6 years, 93% women). Glucocorticoid was used in 148 (65%) patients at baseline (mean dose: 7.3 +/- 6.9 mg/day; 34% > 7.5 mg/day). Osteoporosis (bone mineral density T score <= -2.5) at the hip, femoral neck, or spine was present in 61 (27%) patients. The estimated 10-year risk of major osteoporotic and hip fractures by FRAX was 3.4 +/- 4.5% and 0.95 +/- 2.3%, respectively. After 10 years, three patients developed hip fracture, 6 patients had limb fractures and 20 patients had symptomatic vertebral fractures (major osteoporotic fracture 12.7%, hip fracture 1.3%). The actual major osteoporotic fracture rate was significantly higher than the FRAX estimation (12.7% vs 3.4%; p < 0.001). Logistic regression revealed that osteoporosis (odds ratio (OR): 4.07 [1.51-10.9]), previous fragility fracture (OR: 3.18 [1.02-9.90]), and a parental history of fracture (OR: 4.44 [1.16-17.0]) were independently associated with new clinical fractures at 10 years. Conclusion: The FRAX tool underestimates the major clinical fracture risk at 10 years in patients with SLE.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Ten-year fracture risk by FRAX and osteoporotic fractures in patients with systemic autoimmune diseases
    Lai, E-L
    Huang, W-N
    Chen, H-H
    Hsu, C-Y
    Chen, D-Y
    Hsieh, T-Y
    Hung, W-T
    Lin, C-T
    Lai, K-L
    Tang, K-T
    Chen, Y-M
    Chen, Y-H
    LUPUS, 2019, 28 (08) : 945 - 953
  • [22] Tuberculosis in patients with systemic lupus erythematosus-a 37-year longitudinal survey-based study
    Xiao, X.
    Da, G.
    Xie, X.
    Liu, X.
    Zhang, L.
    Zhou, B.
    Li, H.
    Li, P.
    Yang, H.
    Chen, H.
    Fei, Y.
    Tsokos, G. C.
    Zhao, L.
    Zhang, X.
    JOURNAL OF INTERNAL MEDICINE, 2021, 290 (01) : 101 - 115
  • [23] Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX®) to assess the 10-year probability of fracture
    O. Bruyère
    D. Nicolet
    S. Compère
    V. Rabenda
    P. Jeholet
    B. Zegels
    P. Maassen
    G. Pire
    J. Y. Reginster
    Rheumatology International, 2013, 33 : 979 - 983
  • [24] Imputation of 10-Year Osteoporotic Fracture Rates From Hip Fractures: A Clinical Validation Study
    Leslie, William D.
    Lix, Lisa M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (02) : 388 - 392
  • [25] Prevalence and risk factors of vertebral fracture in female Japanese patients with systemic lupus erythematosus
    Furukawa, Makio
    Kiyohara, Chikako
    Horiuchi, Takahiko
    Tsukamoto, Hiroshi
    Mitoma, Hiroki
    Kimoto, Yasutaka
    Uchino, Ayumi
    Nakagawa, Misato
    Oryoji, Kensuke
    Shimoda, Terufumi
    Harada, Mine
    Akashi, Koichi
    MODERN RHEUMATOLOGY, 2013, 23 (04) : 765 - 773
  • [26] Risk of epilepsy in patients with systemic lupus erythematosus - a retrospective cohort study
    Tsai, Jeng-Dau
    Lin, Cheng-Li
    Lin, Cheng-Chieh
    Sung, Fung-Chang
    Lue, Ko-Huang
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 1635 - 1643
  • [27] Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain
    Rafael Azagra
    Genís Roca
    Gloria Encabo
    Daniel Prieto
    Amada Aguyé
    Marta Zwart
    Sílvia Güell
    Núria Puchol
    Emili Gene
    Enrique Casado
    Pilar Sancho
    Sílvia Solà
    Pere Torán
    Milagros Iglesias
    Victòria Sabaté
    Francesc López-Expósito
    Sergio Ortiz
    Yolanda Fernandez
    Adolf Diez-Perez
    BMC Musculoskeletal Disorders, 12
  • [28] Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX® : a registry study of RA with osteoporosis/fracture
    Cheng, Tien-Tsai
    Yu, Shan-Fu
    Su, Fu-Mei
    Chen, Yin-Chou
    Su, Ben Yu-Jih
    Chiu, Wen-Chan
    Hsu, Chung-Yuan
    Chen, Jia-Feng
    Ko, Chi-Hua
    Lai, Han-Ming
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [29] Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study
    Bizzaro, N.
    Ghirardello, A.
    Zampieri, S.
    Jaccarino, L.
    Tozzoli, R.
    Ruffatti, A.
    Villalta, D.
    Tonutti, E.
    Doria, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (06) : 1158 - 1164
  • [30] Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description
    Adami, S.
    Bianchi, G.
    Brandi, M. L.
    Di Munno, O.
    Frediani, B.
    Gatti, D.
    Giannini, S.
    Girasole, G.
    Minisola, G.
    Minisola, S.
    Nuti, R.
    Pedrazzoni, M.
    Rossini, M.
    Varenna, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : 561 - 570